Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VGNX -- Variagenics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (132)	4/1/2002 7:22:55 PM
From: scaram(o)uche	Respond to of 269

The 10-K today is April Fools, VGNX style. In the pharmaceuticals/biotechnology sector, we have entered into Variagenic® Impact Program collaborations with Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc. In August 2000, we signed a collaborative agreement with Boehringer Ingelheim to utilize our VIP capabilities in the development of a new therapeutic candidate by Boehringer Ingelheim. The goal of the program is to identify genetic markers predictive of therapeutic response, and to use this information in drug development as well as in the development of a diagnostic test. In 2001, we delivered our marker discovery report and we are presently in the final stage of assay development. We entered into VIP agreements with Isis and Amgen in 2000 and 2001, respectively. We have delivered our marker discovery reports under these agreements. At H&Q, Crouch clearly said that the B. Ingelheim assay had transitioned into clinical testing. I believe that I saw or heard it somewhere else recently? Those statements may not be incompatible, but.... if they aren't, I doubt that any non-employees are in on the verbal secret handshake.

To: scaram(o)uche who wrote (132)	4/25/2002 9:21:05 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 269

In addition to the existing terms and conditions of your Employment Agreement and Option Agreements, this Amended and Restated Retention Agreement confirms that if you resign your employment at any time during the Retention Period, so long as you provide a minimum of two (2) weeks advance notice in writing, such resignation shall be treated as a resignation for Good Reason, pursuant to the Employment Agreement, and any cash payments due pursuant to Section 4(b)(i) of the Employment Agreement shall be paid in a lump sum upon the termination of your employment with the Company. In addition, because of the crucial role you have agreed to take on with respect to certain critical objectives during the Retention Period, you shall receive the compensation and benefits noted below, subject to the following conditions: CASH BONUSES....... etc., etc....... Thursday April 25, 9:06 am Eastern Time Press Release SOURCE: VARIAGENICS, INC. VARIAGENICS Announces Senior Management Changes CAMBRIDGE, Mass.--(BW HealthWire)--April 25, 2002--VARIAGENICS, INC. (Nasdaq: VGNX - news), a leader in pharmacogenomics, today announced that Taylor J. Crouch, President and Chief Executive Officer and Director, has resigned effective immediately. The Company also announced that Joseph S. (Jay) Mohr, Vice President of Marketing and Business Development, has been promoted to President and Chief Business Officer. Richard P. Shea will remain Chief Financial Officer and will assume the newly created position of Chief Operating Officer. VARIAGENICS, INC. applies its pharmacogenomic technologies to the discovery, development and commercialization of personalized drugs and companion molecular diagnostic products. Using a drug pathway approach, the Company identifies therapeutically important genetic markers, including SNPs, haplotypes and LOH indicators. This information is then applied to clinical programs to enhance drugs in development, and ultimately to the creation of diagnostics for predicting patient response to drugs. For more information, please visit the Company's website at www.variagenics.com. -------------------------------------------------------------------------------- Contact: VARIAGENICS, INC. Rick Shea Chief Operating Officer 617/588-5354 rshea@variagenics.com